59:@0.895357:0.033217:0.916054:0.033217:0.916054:0.013052:0.895357:0.013052:0.010348:0.010348
HANDBOOK OF GENERAL MEDICINE VOL 1:@0.649278:0.972666:0.923020:0.972666:0.923020:0.958637:0.649278:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
TREATMENT AppROACHEs:@0.983817:0.243404:0.983817:0.056390:0.958557:0.056390:0.958557:0.243404:0.008796:-0.015759:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.114251:0.006043:0.014598:-0.134892:0.158618:-0.158618:0.000000:0.000000:0.000000:0.000000:0.242660:0.009202
TREATMENT AppROACHEs:@0.397039:0.033156:0.624383:0.033156:0.624383:0.013866:0.397039:0.013866:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
or non-fatal ischaemic stroke,  compared to placebo. :@0.076190:0.084931:0.485115:0.084931:0.485115:0.069149:0.076190:0.069149:0.009903:0.004551:0.006562:0.009223:0.009903:0.009223:0.005004:0.004747:0.010326:0.005125:0.010326:0.003024:0.006562:0.003024:0.005866:0.009782:0.009223:0.010326:0.009827:0.014182:0.003024:0.009782:0.006562:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.004188:0.002359:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.006562:0.005125:0.009903:0.006562:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.004188:0.004188
There was no tendency towards heart failure.  :@0.076190:0.099548:0.421026:0.099554:0.421026:0.083771:0.076190:0.083765:0.006441:0.009223:0.009827:0.004551:0.009827:0.004188:0.012564:0.010326:0.005866:0.004188:0.009223:0.009903:0.004188:0.005125:0.009827:0.009223:0.010357:0.009827:0.009223:0.009782:0.008104:0.004188:0.005125:0.009903:0.012564:0.010326:0.004551:0.010357:0.005866:0.004188:0.009223:0.009827:0.010326:0.004551:0.005125:0.004188:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.009677:0.782985
10:@0.407119:0.094255:0.416835:0.094255:0.416835:0.085101:0.407119:0.085101:0.004858:0.004858
The US FDA has included black-box warnings relating :@0.090479:0.114170:0.485146:0.114170:0.485146:0.098387:0.090479:0.098387:0.006441:0.009223:0.009827:0.004823:0.009903:0.007529:0.004838:0.007333:0.011249:0.011188:0.004823:0.009223:0.010326:0.005866:0.004838:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.010357:0.004838:0.010311:0.003024:0.010326:0.009782:0.007590:0.005020:0.010311:0.009903:0.007257:0.004838:0.012564:0.010326:0.004551:0.009223:0.003024:0.009223:0.010175:0.005866:0.004838:0.004551:0.009827:0.003024:0.010326:0.005125:0.003024:0.009223:0.010175:0.004188
to heart failure for both saxagliptin and alogliptin. :@0.076191:0.128787:0.441165:0.128787:0.441165:0.113004:0.076191:0.113004:0.005125:0.009903:0.004188:0.009223:0.009827:0.010326:0.004551:0.005125:0.004188:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.004747:0.009903:0.004551:0.004188:0.010311:0.009903:0.005125:0.009223:0.004188:0.005866:0.010326:0.007257:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.004188:0.010326:0.009223:0.010357:0.004188:0.010326:0.003024:0.009903:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.004188:0.004188
DPP-4 inhibitors and glycaemic control:@0.076190:0.159978:0.391002:0.159978:0.391002:0.141646:0.076190:0.141646:0.011759:0.009407:0.009407:0.007056:0.009407:0.004704:0.004032:0.010079:0.010079:0.004032:0.011087:0.004032:0.005040:0.010751:0.005376:0.007392:0.004704:0.011087:0.010079:0.011087:0.004704:0.011087:0.004032:0.009743:0.010751:0.011087:0.010751:0.015791:0.004032:0.010751:0.004704:0.010751:0.010751:0.010079:0.005040:0.005376:0.010751:0.004032
The influence of DPP-4 inhibitors on the levels of HbA1:@0.076190:0.176772:0.475303:0.176772:0.475303:0.160989:0.076190:0.160989:0.006441:0.009223:0.009827:0.005277:0.003024:0.009223:0.003666:0.003666:0.009192:0.009827:0.009223:0.009782:0.009827:0.005292:0.009903:0.004747:0.005292:0.011249:0.008950:0.008950:0.005020:0.008376:0.005292:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.005292:0.009903:0.009223:0.005292:0.005125:0.009223:0.009827:0.005292:0.003024:0.009827:0.008376:0.009827:0.003024:0.005866:0.005307:0.009903:0.004747:0.005292:0.010326:0.010311:0.011188:0.008376
c:@0.475279:0.176438:0.480952:0.176438:0.480952:0.167284:0.475279:0.167284:0.005674
 :@0.480952:0.176772:0.485140:0.176772:0.485140:0.160989:0.480952:0.160989:0.004188
as monotherapy or in combination with other oral anti-:@0.076185:0.191388:0.480937:0.191388:0.480937:0.175605:0.076185:0.175605:0.010326:0.005866:0.004762:0.014182:0.009903:0.009223:0.009903:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004747:0.009903:0.004551:0.004762:0.003024:0.009223:0.004762:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.004762:0.012564:0.003024:0.005125:0.009223:0.004762:0.009903:0.005125:0.009223:0.009827:0.004551:0.004747:0.009903:0.004551:0.010326:0.003024:0.004762:0.010326:0.009223:0.005125:0.003024:0.005020
diabetic drugs,  has been  evaluated in  multiple trials. :@0.076185:0.206005:0.485125:0.206005:0.485125:0.190222:0.076185:0.190222:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.007378:0.010357:0.004551:0.009192:0.010175:0.005866:0.004188:0.004188:0.003175:0.009223:0.010326:0.005866:0.007378:0.010311:0.009827:0.009827:0.009223:0.004188:0.003175:0.009827:0.008376:0.010326:0.003024:0.009192:0.010326:0.005125:0.009827:0.010357:0.007378:0.003024:0.009223:0.004188:0.003175:0.014182:0.009192:0.003024:0.005125:0.003024:0.010311:0.003024:0.009827:0.007378:0.005125:0.004551:0.003024:0.010326:0.003024:0.005866:0.004188:0.004188
The results of these important trials were reviewed.  sit-:@0.076185:0.220621:0.480944:0.220638:0.480944:0.204856:0.076185:0.204839:0.006441:0.009223:0.009827:0.004732:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.005866:0.004732:0.009903:0.004747:0.004732:0.005125:0.009223:0.009827:0.005866:0.009827:0.004732:0.003024:0.014182:0.010311:0.009903:0.004551:0.005125:0.010326:0.009223:0.005125:0.004732:0.005125:0.004551:0.003024:0.010326:0.003024:0.005866:0.004747:0.012564:0.009827:0.004551:0.009827:0.004732:0.004551:0.009827:0.008376:0.003024:0.009827:0.012564:0.009827:0.010357:0.004188:0.009728:0.004732:0.007529:0.003024:0.005125:0.565336
11:@0.445794:0.215340:0.455510:0.215340:0.455510:0.206186:0.445794:0.206186:0.004858:0.004858
agliptin showed an average reduction in HbA1  levels :@0.076177:0.235255:0.485127:0.235260:0.485127:0.219478:0.076177:0.219472:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.005836:0.005866:0.009223:0.009903:0.012564:0.009827:0.010357:0.005821:0.010326:0.009223:0.005821:0.010326:0.008376:0.009827:0.004551:0.010326:0.010175:0.009827:0.005821:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.005821:0.003024:0.009223:0.005821:0.010326:0.010311:0.011188:0.008376:0.005695:0.005821:0.003024:0.009827:0.008376:0.009827:0.003024:0.005866:0.541174
c:@0.429500:0.234926:0.435173:0.234926:0.435173:0.225772:0.429500:0.225772:0.005674
of 0.67% after 52 weeks of treatment.  Treatment  with :@0.076187:0.249877:0.485142:0.249877:0.485142:0.234094:0.076187:0.234094:0.009903:0.004747:0.006925:0.008376:0.004188:0.008376:0.008376:0.011717:0.006925:0.010326:0.004747:0.005125:0.009827:0.004551:0.006925:0.008376:0.008376:0.006925:0.012564:0.009827:0.009827:0.007590:0.005866:0.006925:0.009903:0.004747:0.006925:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.004188:0.002721:0.006441:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.002721:0.012564:0.003024:0.005125:0.009223:0.004188
saxagliptin showed an average decrease in HbA1  lev-:@0.076187:0.264494:0.480948:0.264505:0.480948:0.248722:0.076187:0.248711:0.005866:0.010326:0.007257:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.004536:0.005866:0.009223:0.009903:0.012564:0.009827:0.010357:0.004521:0.010326:0.009223:0.004521:0.010326:0.008376:0.009827:0.004551:0.010326:0.010175:0.009827:0.004521:0.010357:0.009827:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.004521:0.003024:0.009223:0.004521:0.010326:0.010311:0.011188:0.008376:0.005664:0.004521:0.003024:0.009827:0.008376:0.507888
c:@0.444507:0.264171:0.450181:0.264171:0.450181:0.255017:0.444507:0.255017:0.005674
els of 0.43-1.17%. Treatment with vildagliptin showed an :@0.076196:0.279121:0.485136:0.279121:0.485136:0.263339:0.076196:0.263339:0.009827:0.003024:0.005866:0.004430:0.009903:0.004747:0.004415:0.008376:0.004188:0.008376:0.008376:0.005020:0.008376:0.004188:0.008376:0.008376:0.011732:0.004188:0.004415:0.006441:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004415:0.012564:0.003024:0.005125:0.009223:0.004415:0.008376:0.003024:0.003024:0.010357:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.004445:0.005866:0.009223:0.009903:0.012564:0.009827:0.010357:0.004415:0.010326:0.009223:0.004188
average decrease in HbA1  levels of 1.4% after 24 weeks :@0.076196:0.293738:0.485142:0.293749:0.485142:0.277967:0.076196:0.277955:0.010326:0.008376:0.009827:0.004551:0.010326:0.010175:0.009827:0.003175:0.010357:0.009827:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.003175:0.003024:0.009223:0.003175:0.010326:0.010311:0.011188:0.008376:0.005676:0.003175:0.003024:0.009827:0.008376:0.009827:0.003024:0.005866:0.003190:0.009903:0.004747:0.003175:0.008376:0.004188:0.008376:0.011717:0.003175:0.010326:0.004747:0.005125:0.009827:0.004551:0.003175:0.008376:0.008376:0.003190:0.012564:0.009827:0.009827:0.007590:0.005866:0.464565
c:@0.271945:0.293415:0.277619:0.293415:0.277619:0.284261:0.271945:0.284261:0.005674
as monotherapy in a subgroup of patients with no prior :@0.076188:0.308366:0.485157:0.308366:0.485157:0.292583:0.076188:0.292583:0.010326:0.005866:0.004551:0.014182:0.009903:0.009223:0.009903:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004551:0.003024:0.009223:0.004551:0.010326:0.004551:0.005866:0.009192:0.010311:0.010175:0.004551:0.009903:0.009192:0.010311:0.004551:0.009903:0.004747:0.004551:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004551:0.012564:0.003024:0.005125:0.009223:0.004551:0.009223:0.009903:0.004551:0.010311:0.004551:0.003024:0.009903:0.004551:0.004188
oral  treatment.  A  meta-analysis included information :@0.076188:0.322982:0.485127:0.322982:0.485127:0.307200:0.076188:0.307200:0.009903:0.004551:0.010326:0.003024:0.004188:0.003810:0.005125:0.004551:0.009812:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.004188:0.003810:0.011188:0.004188:0.003810:0.014182:0.009827:0.005125:0.010326:0.005020:0.010326:0.009223:0.010326:0.003024:0.008104:0.005866:0.003024:0.005866:0.008013:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.010357:0.008013:0.003024:0.009223:0.004747:0.009903:0.004551:0.014182:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188
regarding treatment of type 2 diabetes with sitagliptin :@0.076188:0.337599:0.485112:0.337599:0.485112:0.321816:0.076188:0.321816:0.004551:0.009827:0.010175:0.010326:0.004551:0.010357:0.003024:0.009223:0.010175:0.005700:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.005700:0.009903:0.004747:0.005715:0.005125:0.008104:0.010311:0.009827:0.005715:0.008376:0.005715:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.005715:0.012564:0.003024:0.005125:0.009223:0.005715:0.005866:0.003024:0.005125:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.004188
and vildagliptin for ≥12 weeks, compared with placebo :@0.076188:0.352215:0.485127:0.352215:0.485127:0.336433:0.076188:0.336433:0.010326:0.009223:0.010357:0.004158:0.008376:0.003024:0.003024:0.010357:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.004173:0.004747:0.009903:0.004551:0.004143:0.008300:0.008376:0.008376:0.004158:0.012564:0.009827:0.009827:0.007590:0.005866:0.004188:0.004143:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.004143:0.012564:0.003024:0.005125:0.009223:0.004143:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.004188
and other  oral antidiabetic drugs.  This showed a re-:@0.076188:0.366832:0.480960:0.366860:0.480960:0.351078:0.076188:0.351049:0.010326:0.009223:0.010357:0.006607:0.009903:0.005125:0.009223:0.009827:0.004551:0.004188:0.002404:0.009903:0.004551:0.010326:0.003024:0.006607:0.010326:0.009223:0.005125:0.003024:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.006607:0.010357:0.004551:0.009192:0.010175:0.005866:0.004188:0.009712:0.006607:0.006441:0.009223:0.003024:0.005866:0.006667:0.005866:0.009223:0.009903:0.012564:0.009827:0.010357:0.006607:0.010326:0.006607:0.004551:0.009827:0.373838
12:@0.332735:0.361562:0.342451:0.361562:0.342451:0.352408:0.332735:0.352408:0.004858:0.004858
 :@0.373615:0.366860:0.377848:0.366860:0.377848:0.350362:0.373615:0.350362:0.004233
duction of 0.74% in HbA1  levels. In studies with combi-:@0.076193:0.381477:0.480927:0.381483:0.480927:0.365700:0.076193:0.365694:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.005125:0.009903:0.004747:0.005125:0.008376:0.004188:0.008376:0.008376:0.011717:0.005125:0.003024:0.009223:0.005125:0.010326:0.010311:0.011188:0.008376:0.005681:0.005125:0.003024:0.009827:0.008376:0.009827:0.003024:0.005866:0.004188:0.005125:0.003417:0.009223:0.005125:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.005125:0.012564:0.003024:0.005125:0.009223:0.005125:0.009782:0.009903:0.014182:0.010311:0.003024:0.354724
c:@0.261440:0.381148:0.267113:0.381148:0.267113:0.371994:0.261440:0.371994:0.005674
nation therapy of Dpp-4 inhibitors and metformin in one :@0.076190:0.396099:0.485115:0.396099:0.485115:0.380316:0.076190:0.380316:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.004264:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004264:0.009903:0.004747:0.004264:0.011249:0.008950:0.008950:0.005020:0.008376:0.004264:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004264:0.010326:0.009223:0.010357:0.004264:0.014182:0.009827:0.005125:0.004747:0.009903:0.004551:0.014182:0.003024:0.009223:0.004264:0.003024:0.009223:0.004264:0.009903:0.009223:0.009827:0.004188
pill, the results have been synergistic, probably because :@0.076190:0.410716:0.485130:0.410716:0.485130:0.394933:0.076190:0.394933:0.010311:0.003024:0.003024:0.003024:0.004188:0.003704:0.005125:0.009223:0.009827:0.003689:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.005866:0.003704:0.009223:0.010326:0.008376:0.009827:0.003704:0.010311:0.009827:0.009827:0.009223:0.003689:0.005866:0.008104:0.009223:0.009827:0.004551:0.010175:0.003024:0.005866:0.005125:0.003024:0.009782:0.004188:0.003689:0.010311:0.004551:0.009903:0.010311:0.010326:0.010311:0.003024:0.008104:0.003704:0.010311:0.009827:0.009782:0.010326:0.009192:0.005866:0.009827:0.004188
metformin  has  an  upregulating  effect  on  the  level of :@0.076190:0.425332:0.485145:0.425332:0.485145:0.409549:0.076190:0.409549:0.014182:0.009827:0.005125:0.004747:0.009903:0.004551:0.014182:0.003024:0.009223:0.004188:0.002661:0.009223:0.010326:0.005866:0.004188:0.002661:0.010326:0.009223:0.004188:0.002661:0.009192:0.010311:0.004551:0.009827:0.010175:0.009192:0.003024:0.010326:0.005125:0.003024:0.009223:0.010175:0.004188:0.002661:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.004188:0.002661:0.009903:0.009223:0.004188:0.002661:0.005125:0.009223:0.009827:0.004188:0.002661:0.003024:0.009827:0.008376:0.009827:0.003024:0.006864:0.009903:0.004747:0.004188
glucagon-like peptide 1 (GLp-1), enhancing the incre-:@0.076190:0.439949:0.480942:0.439949:0.480942:0.424166:0.076190:0.424166:0.010175:0.003024:0.009192:0.009782:0.010326:0.010175:0.009903:0.009223:0.005020:0.003024:0.003024:0.007590:0.009827:0.005639:0.010311:0.009827:0.010311:0.005125:0.003024:0.010357:0.009827:0.005639:0.008376:0.005639:0.005579:0.013184:0.006985:0.008950:0.005020:0.008376:0.005579:0.004188:0.005639:0.009827:0.009223:0.009223:0.010326:0.009223:0.009782:0.003024:0.009223:0.010175:0.005624:0.005125:0.009223:0.009827:0.005639:0.003024:0.009223:0.009782:0.004551:0.009827:0.005020
tin effect of the Dpp-4 inhibitors. Another possibility for :@0.076190:0.454565:0.485130:0.454565:0.485130:0.438783:0.076190:0.438783:0.005125:0.003024:0.009223:0.006093:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.006078:0.009903:0.004747:0.006078:0.005125:0.009223:0.009827:0.006078:0.011249:0.008950:0.008950:0.005020:0.008376:0.006093:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.006078:0.011188:0.009223:0.009903:0.005125:0.009223:0.009827:0.004551:0.006063:0.010311:0.009903:0.005866:0.005866:0.003024:0.010311:0.003024:0.003024:0.003024:0.005125:0.008104:0.006108:0.004747:0.009903:0.004551:0.004188
the improved results in the combined drug is improved :@0.076190:0.469182:0.485130:0.469182:0.485130:0.453399:0.076190:0.453399:0.005125:0.009223:0.009827:0.004974:0.003024:0.014182:0.010311:0.004551:0.009903:0.008376:0.009827:0.010357:0.004989:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.005866:0.004989:0.003024:0.009223:0.004989:0.005125:0.009223:0.009827:0.004974:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.009827:0.010357:0.004989:0.010357:0.004551:0.009192:0.010175:0.004974:0.003024:0.005866:0.004989:0.003024:0.014182:0.010311:0.004551:0.009903:0.008376:0.009827:0.010357:0.004188
compliance when taking one oral drug instead of two.:@0.076190:0.483798:0.476587:0.483798:0.476587:0.468016:0.076190:0.468016:0.009782:0.009903:0.014182:0.010311:0.003024:0.003024:0.010326:0.009223:0.009782:0.009827:0.004188:0.012564:0.009223:0.009827:0.009223:0.004188:0.005125:0.010326:0.007590:0.003024:0.009223:0.010175:0.004188:0.009903:0.009223:0.009827:0.004188:0.009903:0.004551:0.010326:0.003024:0.004188:0.010357:0.004551:0.009192:0.010175:0.004188:0.003024:0.009223:0.005866:0.005125:0.009827:0.010326:0.010357:0.004188:0.009903:0.004747:0.004188:0.005125:0.012564:0.009903:0.004188
Dpp-4 Inhibitors are  all considered  largely weight-:@0.090478:0.498415:0.480957:0.498415:0.480957:0.482632:0.090478:0.482632:0.011249:0.008950:0.008950:0.005020:0.008376:0.009419:0.003417:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.009419:0.010326:0.004551:0.009827:0.004188:0.005216:0.010326:0.003024:0.003024:0.009419:0.009782:0.009903:0.009223:0.005866:0.003024:0.010357:0.009827:0.004551:0.009827:0.010357:0.004188:0.005216:0.003024:0.010326:0.004551:0.010175:0.009827:0.003024:0.008104:0.009419:0.012564:0.009827:0.003024:0.010175:0.009223:0.005125:0.005020
neutral, and since their effects are glucose-dependent, :@0.076190:0.513031:0.485130:0.513031:0.485130:0.497249:0.076190:0.497249:0.009223:0.009827:0.009192:0.005125:0.004551:0.010326:0.003024:0.004188:0.004037:0.010326:0.009223:0.010357:0.004052:0.005866:0.003024:0.009223:0.009782:0.009827:0.004037:0.005125:0.009223:0.009827:0.003024:0.004551:0.004037:0.009827:0.004747:0.004747:0.009827:0.009782:0.005110:0.005866:0.004052:0.010326:0.004551:0.009827:0.004037:0.010175:0.003024:0.009192:0.009782:0.009903:0.005866:0.009827:0.005020:0.010357:0.009827:0.010311:0.009827:0.009223:0.010357:0.009827:0.009223:0.005125:0.004188:0.004188
hypoglycaemia is rare (unless the drug is combined with :@0.076190:0.527648:0.485145:0.527648:0.485145:0.511865:0.076190:0.511865:0.009223:0.008104:0.010311:0.009903:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.010326:0.003477:0.003024:0.005866:0.003492:0.004551:0.010326:0.004551:0.009827:0.003477:0.005579:0.009192:0.009223:0.003024:0.009827:0.005866:0.005866:0.003477:0.005125:0.009223:0.009827:0.003477:0.010357:0.004551:0.009192:0.010175:0.003477:0.003024:0.005866:0.003492:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.009827:0.010357:0.003477:0.012564:0.003024:0.005125:0.009223:0.004188
a sulphonylurea/insulin).:@0.076190:0.542264:0.251420:0.542264:0.251420:0.526482:0.076190:0.526482:0.010326:0.004188:0.005866:0.009192:0.003024:0.010311:0.009223:0.009903:0.009223:0.008104:0.003024:0.009192:0.004551:0.009827:0.010326:0.006607:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.005579:0.004188
sGlt2 inhibitors :@0.076190:0.573506:0.204198:0.573506:0.204198:0.555175:0.076190:0.555175:0.008735:0.014111:0.007392:0.007056:0.009407:0.004704:0.004032:0.010079:0.010079:0.004032:0.011087:0.004032:0.005040:0.010751:0.005376:0.007392:0.004704
sGLT2 (sodium-glucose cotransporter-2) inhibitors are a :@0.076190:0.590300:0.485130:0.590300:0.485130:0.574518:0.076190:0.574518:0.007529:0.013184:0.006985:0.006441:0.008376:0.005004:0.005579:0.005866:0.009903:0.010357:0.003024:0.009192:0.014182:0.005020:0.010175:0.003024:0.009192:0.009782:0.009903:0.005866:0.009827:0.005004:0.009782:0.009903:0.005125:0.004551:0.010326:0.009223:0.005866:0.010311:0.009903:0.004551:0.005125:0.009827:0.004551:0.005020:0.008376:0.005579:0.005020:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.005004:0.010326:0.004551:0.009827:0.004989:0.010326:0.004188
 :@0.367595:0.590300:0.371828:0.590300:0.371828:0.573802:0.367595:0.573802:0.004233
class of medicines that are FDA-approved for use with :@0.076175:0.604917:0.485115:0.604917:0.485115:0.589134:0.076175:0.589134:0.009782:0.003024:0.010326:0.005866:0.005866:0.005367:0.009903:0.004747:0.005352:0.014182:0.009827:0.010357:0.003024:0.009782:0.003024:0.009223:0.009827:0.005866:0.005367:0.005125:0.009223:0.010326:0.005125:0.005352:0.010326:0.004551:0.009827:0.005352:0.007333:0.011249:0.011188:0.005020:0.010326:0.010311:0.010311:0.004551:0.009903:0.008376:0.009827:0.010357:0.005352:0.004747:0.009903:0.004551:0.005352:0.009192:0.005866:0.009827:0.005352:0.012564:0.003024:0.005125:0.009223:0.004188
diet and exercise to  lower  blood  sugar  in adults with :@0.076175:0.619533:0.485130:0.619533:0.485130:0.603751:0.076175:0.603751:0.010357:0.003024:0.009827:0.005125:0.006894:0.010326:0.009223:0.010357:0.006894:0.009827:0.007257:0.009827:0.004551:0.009782:0.003024:0.005866:0.009827:0.006894:0.005125:0.009903:0.004188:0.002691:0.003024:0.009903:0.012564:0.009827:0.004551:0.004188:0.002691:0.010311:0.003024:0.009903:0.009903:0.010357:0.004188:0.002691:0.005866:0.009192:0.010175:0.010326:0.004551:0.004188:0.002691:0.003024:0.009223:0.006894:0.010326:0.010357:0.009192:0.003024:0.005125:0.005866:0.006894:0.012564:0.003024:0.005125:0.009223:0.004188
type 2 diabetes. Drugs in this class include empagliflozin, :@0.076175:0.634150:0.485085:0.634150:0.485085:0.618367:0.076175:0.618367:0.005125:0.008104:0.010311:0.009827:0.003417:0.008376:0.003417:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.003417:0.011249:0.004551:0.009192:0.010175:0.005866:0.003417:0.003024:0.009223:0.003417:0.005125:0.009223:0.003024:0.005866:0.003417:0.009782:0.003024:0.010326:0.005866:0.005866:0.003432:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.003417:0.009827:0.014182:0.010311:0.010326:0.010175:0.003024:0.003024:0.003666:0.003666:0.009903:0.006426:0.003024:0.009223:0.004188:0.004188
canagliflozin, and dapagliflozin (see Table 3). :@0.076175:0.648767:0.420148:0.648767:0.420148:0.632984:0.076175:0.632984:0.009782:0.010326:0.009223:0.010326:0.010175:0.003024:0.003024:0.003666:0.003666:0.009903:0.006426:0.003024:0.009223:0.004188:0.006244:0.010326:0.009223:0.010357:0.006259:0.010357:0.010326:0.010311:0.010326:0.010175:0.003024:0.003024:0.003666:0.003666:0.009903:0.006426:0.003024:0.009223:0.006259:0.005579:0.005866:0.009827:0.009827:0.006259:0.006441:0.010326:0.010311:0.003024:0.009827:0.006259:0.008376:0.005579:0.004188:0.004188
Figure 2 :@0.422205:0.648767:0.485115:0.648767:0.485115:0.632984:0.422205:0.632984:0.007333:0.003024:0.010175:0.009192:0.004551:0.009827:0.006244:0.008376:0.004188
illustrates their mechanism of action:@0.076175:0.663383:0.337296:0.663383:0.337296:0.647600:0.076175:0.647600:0.003024:0.003024:0.003024:0.009192:0.005866:0.005125:0.004551:0.010326:0.005125:0.009827:0.005866:0.004188:0.005125:0.009223:0.009827:0.003024:0.004551:0.004188:0.014182:0.009827:0.009782:0.009223:0.010326:0.009223:0.003024:0.005866:0.014182:0.004188:0.009903:0.004747:0.004188:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223
table 3. sGlt2 inhibitors:@0.077030:0.696827:0.248783:0.696827:0.248783:0.680329:0.077030:0.680329:0.006350:0.009979:0.009979:0.003629:0.009676:0.004233:0.008467:0.004233:0.004233:0.007862:0.012700:0.006652:0.006350:0.008467:0.004233:0.003629:0.009071:0.009071:0.003629:0.009979:0.003629:0.004536:0.009676:0.004838:0.006652
Generic:@0.082070:0.715676:0.134751:0.715676:0.134751:0.701010:0.082070:0.701010:0.011289:0.008601:0.008063:0.008601:0.004301:0.003225:0.008601
trade name:@0.216435:0.715676:0.294650:0.715676:0.294650:0.701010:0.216435:0.701010:0.005644:0.004301:0.008870:0.008870:0.008601:0.003763:0.008063:0.008870:0.012633:0.008601
trial:@0.350799:0.715676:0.376065:0.715676:0.376065:0.701010:0.350799:0.701010:0.005644:0.004301:0.003225:0.008870:0.003225
Empagliflozin:@0.082083:0.731070:0.166575:0.731070:0.166575:0.717041:0.082083:0.717041:0.007203:0.012606:0.009165:0.009179:0.009045:0.002688:0.002688:0.003259:0.003259:0.008803:0.005712:0.002688:0.008198
Jardiance:@0.216448:0.731070:0.282851:0.731070:0.282851:0.717041:0.216448:0.717041:0.006478:0.009179:0.004045:0.009206:0.002688:0.009179:0.008198:0.008695:0.008735
EMpA-REG :@0.350813:0.731070:0.423532:0.731070:0.423532:0.717041:0.350813:0.717041:0.007203:0.012351:0.007956:0.009945:0.004462:0.008158:0.007203:0.011719:0.003723
Outcome:@0.350813:0.743898:0.414057:0.743898:0.414057:0.729869:0.350813:0.729869:0.011679:0.008171:0.004556:0.008695:0.008803:0.012606:0.008735
Canagliflozin:@0.082097:0.759292:0.165917:0.759292:0.165917:0.745263:0.082097:0.745263:0.010926:0.009179:0.008198:0.009179:0.009045:0.002688:0.002688:0.003259:0.003259:0.008803:0.005712:0.002688:0.008198
Invokana:@0.216461:0.759292:0.277247:0.759292:0.277247:0.745263:0.216461:0.745263:0.003037:0.008198:0.007445:0.008803:0.006746:0.009179:0.008198:0.009179
CANVAs, :@0.350826:0.759292:0.415146:0.759292:0.415146:0.745263:0.350826:0.745263:0.010926:0.009945:0.009945:0.009434:0.009945:0.006693:0.003709:0.003723
CANVAs-R:@0.350826:0.772120:0.420333:0.772120:0.420333:0.758091:0.350826:0.758091:0.010926:0.009945:0.009945:0.009434:0.009945:0.006693:0.004462:0.008158
Dapagliflozin:@0.082110:0.787514:0.165971:0.787514:0.165971:0.773485:0.082110:0.773485:0.009999:0.009179:0.009165:0.009179:0.009045:0.002688:0.002688:0.003259:0.003259:0.008803:0.005712:0.002688:0.008198
Forxiga:@0.216475:0.787514:0.263203:0.787514:0.263203:0.773485:0.216475:0.773485:0.006518:0.008803:0.004045:0.006451:0.002688:0.009045:0.009179
DECLARE- :@0.350839:0.787514:0.418667:0.787514:0.418667:0.773485:0.350839:0.773485:0.009999:0.007203:0.010926:0.006209:0.009945:0.008158:0.007203:0.004462:0.003723
TIMI 58:@0.350839:0.800342:0.393603:0.800342:0.393603:0.786313:0.350839:0.786313:0.005725:0.003037:0.012351:0.003037:0.003723:0.007445:0.007445
Ertugliflozin:@0.082124:0.815736:0.152437:0.815736:0.152437:0.801707:0.082124:0.801707:0.007203:0.004045:0.004556:0.008171:0.009045:0.002688:0.002688:0.003259:0.003259:0.008803:0.005712:0.002688:0.008198
steglatro:@0.216488:0.815736:0.274787:0.815736:0.274787:0.801707:0.216488:0.801707:0.006693:0.004556:0.008735:0.009045:0.002688:0.009179:0.004556:0.004045:0.008803
VERTIs CV:@0.350853:0.815736:0.415186:0.815736:0.415186:0.801707:0.350853:0.801707:0.009434:0.007203:0.008158:0.005725:0.003037:0.006693:0.003723:0.010926:0.009434
Sofagliflozin*:@0.082137:0.831130:0.163081:0.831130:0.163081:0.817101:0.082137:0.817101:0.006693:0.008803:0.004220:0.009179:0.009045:0.002688:0.002688:0.003259:0.003259:0.008803:0.005712:0.002688:0.008198:0.005712
sCORED:@0.350853:0.831130:0.405510:0.831130:0.405510:0.817101:0.350853:0.817101:0.006693:0.010926:0.011679:0.008158:0.007203:0.009999
*Dual sGLT1and sGLT2 inhibitor:@0.082070:0.845168:0.257165:0.845168:0.257165:0.832893:0.082070:0.832893:0.004998:0.008749:0.007150:0.008032:0.002352:0.003257:0.005856:0.010254:0.005433:0.005009:0.006515:0.008032:0.007173:0.008055:0.003257:0.005856:0.010254:0.005433:0.005009:0.006515:0.003257:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.007702:0.003540
Ninety percent of glucose filtered through the glomeru:@0.090476:0.874817:0.476420:0.874817:0.476420:0.859035:0.090476:0.859035:0.010735:0.002570:0.008769:0.009374:0.004672:0.007650:0.005186:0.009858:0.009374:0.004097:0.009328:0.009374:0.008769:0.004672:0.005186:0.009449:0.004294:0.005186:0.009722:0.002570:0.008739:0.009328:0.009449:0.005413:0.009374:0.005186:0.003455:0.003455:0.002570:0.004672:0.009374:0.004097:0.009374:0.009903:0.005186:0.004672:0.008769:0.004097:0.009449:0.008739:0.009722:0.008769:0.005186:0.004672:0.008769:0.009374:0.005186:0.009722:0.002570:0.009449:0.013728:0.009374:0.004097:0.009192
-:@0.475966:0.874817:0.480986:0.874817:0.480986:0.859035:0.475966:0.859035:0.005020
lus is normally reabsorbed by the s1 segment of the proxi-:@0.076189:0.888926:0.480940:0.888926:0.480940:0.873143:0.076189:0.873143:0.002570:0.008739:0.005413:0.004929:0.002570:0.005413:0.004929:0.008769:0.009449:0.004097:0.013728:0.009873:0.002570:0.002570:0.007650:0.004929:0.004097:0.009374:0.009873:0.009858:0.005413:0.009449:0.004097:0.009858:0.009374:0.009903:0.004929:0.009858:0.007650:0.004929:0.004672:0.008769:0.009374:0.004959:0.007076:0.007922:0.004929:0.005413:0.009374:0.009722:0.013728:0.009374:0.008769:0.004672:0.004929:0.009449:0.004294:0.004929:0.004672:0.008769:0.009374:0.004929:0.009858:0.004097:0.009449:0.006804:0.002570:0.005020
mal tubule by the sGLT2 receptors. Inhibition of the sGLT2 :@0.076189:0.903034:0.485174:0.903034:0.485174:0.887252:0.076189:0.887252:0.013728:0.009873:0.002570:0.005156:0.004672:0.008739:0.009858:0.008739:0.002570:0.009374:0.005171:0.009858:0.007650:0.005171:0.004672:0.008769:0.009374:0.005171:0.007076:0.012730:0.006531:0.005987:0.007922:0.005156:0.004097:0.009374:0.009328:0.009374:0.009858:0.004672:0.009449:0.004097:0.005413:0.003734:0.005156:0.002963:0.008769:0.008769:0.002570:0.009858:0.002570:0.004672:0.002570:0.009449:0.008769:0.005171:0.009449:0.004294:0.005171:0.004672:0.008769:0.009374:0.005171:0.007076:0.012730:0.006531:0.005987:0.008376:0.004188
receptors blocks this reabsorption with resultant glycosuria. :@0.076189:0.917143:0.485174:0.917143:0.485174:0.901360:0.076189:0.901360:0.004097:0.009374:0.009328:0.009374:0.009858:0.004672:0.009449:0.004097:0.005413:0.004430:0.009858:0.002570:0.009449:0.009328:0.007136:0.005413:0.004430:0.004672:0.008769:0.002570:0.005413:0.004430:0.004097:0.009374:0.009873:0.009858:0.005413:0.009449:0.004097:0.009858:0.004672:0.002570:0.009449:0.008769:0.004430:0.012110:0.002570:0.004672:0.008769:0.004430:0.004097:0.009374:0.005413:0.008739:0.002570:0.004672:0.009873:0.008769:0.004672:0.004430:0.009722:0.002570:0.007650:0.009328:0.009449:0.005413:0.008739:0.004097:0.002570:0.009873:0.004188:0.004188
This glucose loss leads to a drop in blood-glucose levels, en-:@0.076189:0.931251:0.480971:0.931251:0.480971:0.915469:0.076189:0.915469:0.005987:0.008769:0.002570:0.005413:0.003432:0.009722:0.002570:0.008739:0.009328:0.009449:0.005413:0.009374:0.003432:0.002570:0.009449:0.005413:0.005413:0.003432:0.002570:0.009374:0.009873:0.009903:0.005413:0.003432:0.004672:0.009449:0.003432:0.009873:0.003432:0.009903:0.004097:0.009449:0.009858:0.003432:0.002570:0.008769:0.003432:0.009858:0.002570:0.009449:0.009449:0.009903:0.004566:0.009722:0.002570:0.008739:0.009328:0.009449:0.005413:0.009374:0.003432:0.002570:0.009374:0.007922:0.009374:0.002570:0.005413:0.003734:0.003432:0.009374:0.008769:0.005020
ergy (and weight) loss, and a reduction in blood pressure.:@0.076189:0.945360:0.471672:0.945360:0.471672:0.929577:0.076189:0.929577:0.009374:0.004097:0.009722:0.007650:0.003734:0.005125:0.009873:0.008769:0.009903:0.003734:0.012110:0.009374:0.002570:0.009722:0.008769:0.004672:0.005125:0.003734:0.002570:0.009449:0.005413:0.005413:0.003734:0.003734:0.009873:0.008769:0.009903:0.003734:0.009873:0.003734:0.004097:0.009374:0.009903:0.008739:0.009328:0.004672:0.002570:0.009449:0.008769:0.003734:0.002570:0.008769:0.003734:0.009858:0.002570:0.009449:0.009449:0.009903:0.003734:0.009858:0.004097:0.009374:0.005413:0.005413:0.008739:0.004097:0.009374:0.004188
eMPA-reG Outcome:@0.519040:0.263024:0.669626:0.263024:0.669626:0.246526:0.519040:0.246526:0.007862:0.013607:0.008467:0.011188:0.006350:0.008769:0.007862:0.012700:0.004233:0.012700:0.009071:0.004536:0.009676:0.009676:0.014212:0.009676
The purpose of the EMpA-REG Outcome trial (the Em-:@0.519040:0.280388:0.923822:0.280388:0.923822:0.264606:0.519040:0.264606:0.006441:0.009223:0.009827:0.006078:0.010311:0.009192:0.004551:0.010311:0.009903:0.005866:0.009827:0.006078:0.009903:0.004747:0.006078:0.005125:0.009223:0.009827:0.006078:0.008104:0.013894:0.008950:0.011188:0.005020:0.009177:0.008104:0.013184:0.006078:0.013138:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.006078:0.005125:0.004551:0.003024:0.010326:0.003024:0.006078:0.005579:0.005125:0.009223:0.009827:0.006078:0.008104:0.014182:0.005020
pagliflozin Cardiovascular Outcome Event Trial in Type 2 :@0.519040:0.295190:0.927980:0.295190:0.927980:0.279407:0.519040:0.279407:0.010311:0.010326:0.010175:0.003024:0.003024:0.003666:0.003666:0.009903:0.006426:0.003024:0.009223:0.003659:0.012292:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.003659:0.013138:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.003659:0.008104:0.008376:0.009827:0.009223:0.005125:0.003659:0.006441:0.004551:0.003024:0.010326:0.003024:0.003659:0.003024:0.009223:0.003659:0.006441:0.008104:0.010311:0.009827:0.003659:0.008376:0.004188
Diabetes Mellitus patients – Removing Excess Glucose) :@0.519040:0.309991:0.927980:0.309991:0.927980:0.294208:0.519040:0.294208:0.011249:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.005715:0.013894:0.009827:0.003024:0.003024:0.003024:0.005125:0.009192:0.005866:0.005715:0.008950:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005700:0.007560:0.005700:0.009177:0.009827:0.014182:0.009903:0.008376:0.003024:0.009223:0.010175:0.005700:0.008104:0.007257:0.009782:0.009827:0.005866:0.005866:0.005715:0.013184:0.003024:0.009192:0.009782:0.009903:0.005866:0.009827:0.005579:0.004188
was to evaluate the cardiovascular effect of empagli-:@0.519040:0.324792:0.923777:0.324792:0.923777:0.309010:0.519040:0.309010:0.012564:0.010326:0.005866:0.005261:0.005125:0.009903:0.005246:0.009827:0.008376:0.010326:0.003024:0.009192:0.010326:0.005125:0.009827:0.005261:0.005125:0.009223:0.009827:0.005246:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005261:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005246:0.009903:0.004747:0.005246:0.009827:0.014182:0.010311:0.010326:0.010175:0.003024:0.003024:0.005020
flozin, as compared with placebo, in addition to stand:@0.519040:0.339593:0.918772:0.339593:0.918772:0.323811:0.519040:0.323811:0.003666:0.003666:0.009903:0.006426:0.003024:0.009223:0.004188:0.004626:0.010326:0.005866:0.004642:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.004626:0.012564:0.003024:0.005125:0.009223:0.004642:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.004188:0.004642:0.003024:0.009223:0.004642:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.004642:0.005125:0.009903:0.004626:0.005866:0.005125:0.010326:0.009223:0.010357
-:@0.918772:0.339593:0.923792:0.339593:0.923792:0.323811:0.918772:0.323811:0.005020
ard of care, in patients with type 2 diabetes at high risk :@0.519040:0.354395:0.927995:0.354395:0.927995:0.338612:0.519040:0.338612:0.010326:0.004551:0.010357:0.004611:0.009903:0.004747:0.004596:0.009782:0.010326:0.004551:0.009827:0.004188:0.004596:0.003024:0.009223:0.004611:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004611:0.012564:0.003024:0.005125:0.009223:0.004611:0.005125:0.008104:0.010311:0.009827:0.004611:0.008376:0.004611:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004611:0.010326:0.005125:0.004596:0.009223:0.003024:0.010175:0.009223:0.004596:0.004551:0.003024:0.005866:0.007590:0.004188
of cardiovascular events.:@0.519040:0.369196:0.703886:0.369196:0.703886:0.353413:0.519040:0.353413:0.009903:0.004747:0.004188:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188:0.009827:0.008376:0.009827:0.009223:0.005125:0.005866:0.004188
The conclusions of the EMpA-REG Outcome trial were :@0.533328:0.383997:0.927980:0.383997:0.927980:0.368215:0.533328:0.368215:0.006441:0.009223:0.009827:0.004248:0.009782:0.009903:0.009223:0.009782:0.003024:0.009192:0.005866:0.003024:0.009903:0.009223:0.005866:0.004264:0.009903:0.004747:0.004248:0.005125:0.009223:0.009827:0.004248:0.008104:0.013894:0.008950:0.011188:0.005020:0.009177:0.008104:0.013184:0.004248:0.013138:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.004248:0.005125:0.004551:0.003024:0.010326:0.003024:0.004264:0.012564:0.009827:0.004551:0.009827:0.004188
as follows::@0.519040:0.398799:0.592640:0.398799:0.592640:0.383016:0.519040:0.383016:0.010326:0.005866:0.004188:0.004747:0.009903:0.003024:0.003024:0.009903:0.012564:0.005866:0.004188
•  Empagliflozin had a statistically significant 14% lower :@0.519040:0.413600:0.928010:0.413600:0.928010:0.397817:0.519040:0.397817:0.009162:0.004188:0.006804:0.008104:0.014182:0.010311:0.010326:0.010175:0.003024:0.003024:0.003666:0.003666:0.009903:0.006426:0.003024:0.009223:0.005020:0.009223:0.010326:0.010357:0.005020:0.010326:0.005020:0.005866:0.005125:0.010326:0.005125:0.003024:0.005866:0.005125:0.003024:0.009782:0.010326:0.003024:0.003024:0.008104:0.005035:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.005020:0.008376:0.008376:0.011717:0.005020:0.003024:0.009903:0.012564:0.009827:0.004551:0.004188
rate of MACE than placebo. This benefit was primar:@0.539194:0.428401:0.918757:0.428401:0.918757:0.412618:0.539194:0.412618:0.004551:0.010326:0.005125:0.009827:0.004505:0.009903:0.004747:0.004505:0.013894:0.011188:0.012292:0.008104:0.004521:0.005125:0.009223:0.010326:0.009223:0.004505:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.004188:0.004521:0.006441:0.009223:0.003024:0.005866:0.004521:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.004505:0.012564:0.010326:0.005866:0.004521:0.010311:0.004551:0.003024:0.014182:0.010326:0.004551
-:@0.918757:0.428401:0.923777:0.428401:0.923777:0.412618:0.918757:0.412618:0.005020
ily driven by a 38% relative risk reduction in cardio-:@0.539194:0.443202:0.923807:0.443202:0.923807:0.427420:0.539194:0.427420:0.003024:0.003024:0.008104:0.006290:0.010357:0.004551:0.003024:0.008376:0.009827:0.009223:0.006290:0.010311:0.008104:0.006290:0.010326:0.006290:0.008376:0.008376:0.011717:0.006290:0.004551:0.009827:0.003024:0.010326:0.005125:0.003024:0.008376:0.009827:0.006290:0.004551:0.003024:0.005866:0.007590:0.006290:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.006274:0.003024:0.009223:0.006290:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.005020
vascular death (HR, 0.62; 95% CI, 0.49-0.77; P <.001), :@0.539194:0.458004:0.927965:0.458004:0.927965:0.442221:0.539194:0.442221:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005261:0.010357:0.009827:0.010326:0.005125:0.009223:0.005261:0.005579:0.010326:0.009177:0.004188:0.005261:0.008376:0.004188:0.008376:0.008376:0.004188:0.005261:0.008376:0.008376:0.011717:0.005261:0.012292:0.003417:0.004188:0.005261:0.008376:0.004188:0.008376:0.008376:0.005020:0.008376:0.004188:0.008376:0.008376:0.004188:0.005277:0.008950:0.005261:0.009162:0.004188:0.008376:0.008376:0.008376:0.005579:0.004188:0.004188
with no differences in the risk of MI or stroke, com-:@0.539194:0.472805:0.923792:0.472805:0.923792:0.457022:0.539194:0.457022:0.012564:0.003024:0.005125:0.009223:0.006395:0.009223:0.009903:0.006395:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.005866:0.006395:0.003024:0.009223:0.006395:0.005125:0.009223:0.009827:0.006395:0.004551:0.003024:0.005866:0.007590:0.006395:0.009903:0.004747:0.006395:0.013894:0.003417:0.006395:0.009903:0.004551:0.006395:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.006395:0.009782:0.009903:0.014182:0.005020
pared with placebo (see Figure 3).:@0.539194:0.487606:0.792271:0.487606:0.792271:0.471823:0.539194:0.471823:0.010311:0.010326:0.004551:0.009827:0.010357:0.004188:0.012564:0.003024:0.005125:0.009223:0.004188:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.004188:0.005579:0.005866:0.009827:0.009827:0.004188:0.007333:0.003024:0.010175:0.009192:0.004551:0.009827:0.004188:0.008376:0.005579:0.004188
•  The cardiovascular death rate was reduced by 38% :@0.519040:0.502407:0.927980:0.502407:0.927980:0.486625:0.519040:0.486625:0.009162:0.004188:0.006804:0.006441:0.009223:0.009827:0.005065:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005080:0.010357:0.009827:0.010326:0.005125:0.009223:0.005065:0.004551:0.010326:0.005125:0.009827:0.005065:0.012564:0.010326:0.005866:0.005080:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.005065:0.010311:0.008104:0.005080:0.008376:0.008376:0.011717:0.004188
(see Figure 4) and the all-cause death rate by 32%:@0.539194:0.517209:0.908083:0.517209:0.908083:0.501426:0.539194:0.501426:0.005579:0.005866:0.009827:0.009827:0.004188:0.007333:0.003024:0.010175:0.009192:0.004551:0.009827:0.004188:0.008376:0.005579:0.004188:0.010326:0.009223:0.010357:0.004188:0.005125:0.009223:0.009827:0.004188:0.010326:0.003024:0.003024:0.005020:0.009782:0.010326:0.009192:0.005866:0.009827:0.004188:0.010357:0.009827:0.010326:0.005125:0.009223:0.004188:0.004551:0.010326:0.005125:0.009827:0.004188:0.010311:0.008104:0.004188:0.008376:0.008376:0.011717
•  There was a statistically significant 35% reduction in :@0.519040:0.532010:0.927965:0.532010:0.927965:0.516227:0.519040:0.516227:0.009162:0.004188:0.006804:0.006441:0.009223:0.009827:0.004551:0.009827:0.006138:0.012564:0.010326:0.005866:0.006153:0.010326:0.006153:0.005866:0.005125:0.010326:0.005125:0.003024:0.005866:0.005125:0.003024:0.009782:0.010326:0.003024:0.003024:0.008104:0.006169:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.006153:0.008376:0.008376:0.011717:0.006153:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.006138:0.003024:0.009223:0.004188
heart failure (see Figure 5). These improvements are :@0.539194:0.546811:0.927980:0.546811:0.927980:0.531029:0.539194:0.531029:0.009223:0.009827:0.010326:0.004551:0.005125:0.005307:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.005322:0.005579:0.005866:0.009827:0.009827:0.005322:0.007333:0.003024:0.010175:0.009192:0.004551:0.009827:0.005307:0.008376:0.005579:0.004188:0.005322:0.006441:0.009223:0.009827:0.005866:0.009827:0.005322:0.003024:0.014182:0.010311:0.004551:0.009903:0.008376:0.009827:0.014182:0.009827:0.009223:0.005125:0.005866:0.005322:0.010326:0.004551:0.009827:0.004188
seen very early after therapy, within weeks to months :@0.539194:0.561612:0.927995:0.561612:0.927995:0.545830:0.539194:0.545830:0.005866:0.009827:0.009827:0.009223:0.003810:0.008376:0.009827:0.004551:0.008104:0.003825:0.009827:0.010326:0.004551:0.003024:0.008104:0.003825:0.010326:0.004747:0.005125:0.009827:0.004551:0.003810:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.003810:0.012564:0.003024:0.005125:0.009223:0.003024:0.009223:0.003825:0.012564:0.009827:0.009827:0.007590:0.005866:0.003825:0.005125:0.009903:0.003810:0.014182:0.009903:0.009223:0.005125:0.009223:0.005866:0.004188
(see curve separations in Figures 3-5).:@0.539194:0.576414:0.811064:0.576414:0.811064:0.560631:0.539194:0.560631:0.005579:0.005866:0.009827:0.009827:0.004188:0.009782:0.009192:0.004551:0.008376:0.009827:0.004188:0.005866:0.009827:0.010311:0.010326:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.003024:0.009223:0.004188:0.007333:0.003024:0.010175:0.009192:0.004551:0.009827:0.005866:0.004188:0.008376:0.005020:0.008376:0.005579:0.004188
•  Higher rates of genital infection were seen in patients :@0.519040:0.591215:0.927965:0.591215:0.927965:0.575432:0.519040:0.575432:0.009162:0.004188:0.006804:0.010326:0.003024:0.010175:0.009223:0.009827:0.004551:0.003734:0.004551:0.010326:0.005125:0.009827:0.005866:0.003750:0.009903:0.004747:0.003734:0.010175:0.009827:0.009223:0.003024:0.005125:0.010326:0.003024:0.003750:0.003024:0.009223:0.004747:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.003734:0.012564:0.009827:0.004551:0.009827:0.003734:0.005866:0.009827:0.009827:0.009223:0.003734:0.003024:0.009223:0.003750:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188
on empagliflozin, compared to placebo:@0.539194:0.606016:0.833788:0.606016:0.833788:0.590234:0.539194:0.590234:0.009903:0.009223:0.004188:0.009827:0.014182:0.010311:0.010326:0.010175:0.003024:0.003024:0.003666:0.003666:0.009903:0.006426:0.003024:0.009223:0.004188:0.004188:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.004188:0.005125:0.009903:0.004188:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903
•  No increased risk of euglycaemic diabetic ketoaci:@0.519040:0.620817:0.918788:0.620817:0.918788:0.605035:0.519040:0.605035:0.009162:0.004188:0.006804:0.011188:0.009903:0.005896:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.005912:0.004551:0.003024:0.005866:0.007590:0.005912:0.009903:0.004747:0.005896:0.009827:0.009192:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.009782:0.005912:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.005912:0.007590:0.009827:0.005125:0.009903:0.010326:0.009782:0.003024
-:@0.918788:0.620817:0.923807:0.620817:0.923807:0.605035:0.918788:0.605035:0.005020
dosis (DKA) was seen with the use of empagliflozin in :@0.539194:0.635619:0.927950:0.635619:0.927950:0.619836:0.539194:0.619836:0.010357:0.009903:0.005866:0.003024:0.005866:0.004551:0.005579:0.011249:0.008935:0.011188:0.005579:0.004536:0.012564:0.010326:0.005866:0.004551:0.005866:0.009827:0.009827:0.009223:0.004536:0.012564:0.003024:0.005125:0.009223:0.004536:0.005125:0.009223:0.009827:0.004536:0.009192:0.005866:0.009827:0.004536:0.009903:0.004747:0.004536:0.009827:0.014182:0.010311:0.010326:0.010175:0.003024:0.003024:0.003666:0.003666:0.009903:0.006426:0.003024:0.009223:0.004536:0.003024:0.009223:0.004188
this trial:@0.539194:0.650420:0.592670:0.650420:0.592670:0.634637:0.539194:0.634637:0.005125:0.009223:0.003024:0.005866:0.004188:0.005125:0.004551:0.003024:0.010326:0.003024
•  Weight loss. Glucosuria, produced by SGLT2 inhibitors, :@0.519040:0.665221:0.927980:0.665221:0.927980:0.649439:0.519040:0.649439:0.009162:0.004188:0.006804:0.014514:0.009827:0.003024:0.010175:0.009223:0.005125:0.003160:0.003024:0.009903:0.005866:0.005866:0.004188:0.003160:0.013184:0.003024:0.009192:0.009782:0.009903:0.005866:0.009192:0.004551:0.003024:0.010326:0.004188:0.003160:0.010311:0.004551:0.009903:0.010357:0.009192:0.009782:0.009827:0.010357:0.003160:0.010311:0.008104:0.003160:0.007529:0.013184:0.006985:0.006441:0.008376:0.003160:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.004188
causes calorie loss and a decrease in body weight. In :@0.539194:0.680023:0.927965:0.680023:0.927965:0.664240:0.539194:0.664240:0.009782:0.010326:0.009192:0.005866:0.009827:0.005866:0.003372:0.009782:0.010326:0.003024:0.009903:0.004551:0.003024:0.009827:0.003372:0.003024:0.009903:0.005866:0.005866:0.003372:0.010326:0.009223:0.010357:0.003372:0.010326:0.003372:0.010357:0.009827:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.003372:0.003024:0.009223:0.003372:0.010311:0.009903:0.010357:0.008104:0.003372:0.012564:0.009827:0.003024:0.010175:0.009223:0.005125:0.004188:0.003372:0.003417:0.009223:0.004188
the EMPA-REG OUTCOME study, empagliflozin-treat:@0.539194:0.694824:0.918772:0.694824:0.918772:0.679041:0.539194:0.679041:0.005125:0.009223:0.009827:0.005322:0.008104:0.013894:0.008950:0.011188:0.005020:0.009177:0.008104:0.013184:0.005322:0.013138:0.009903:0.006441:0.012292:0.013138:0.013894:0.008104:0.005322:0.005866:0.005125:0.009192:0.010357:0.008104:0.004188:0.005322:0.009827:0.014182:0.010311:0.010326:0.010175:0.003024:0.003024:0.003666:0.003666:0.009903:0.006426:0.003024:0.009223:0.005020:0.005125:0.004551:0.009827:0.010326:0.005125
-:@0.918772:0.694824:0.923792:0.694824:0.923792:0.679041:0.918772:0.679041:0.005020
ed subjects lost  2 kg:@0.539194:0.709625:0.695993:0.709625:0.695993:0.693842:0.539194:0.693842:0.009827:0.010357:0.004188:0.005866:0.009192:0.010311:0.003069:0.009827:0.009782:0.005125:0.005866:0.004188:0.003024:0.009903:0.005866:0.005125:0.004188:0.010765:0.008376:0.004188:0.007590:0.010175
∼:@0.654900:0.715493:0.665665:0.715493:0.665665:0.699632:0.654900:0.699632:0.010765
•  Hypoglycaemia was rarely found.:@0.519040:0.724426:0.785921:0.724426:0.785921:0.708644:0.519040:0.708644:0.009162:0.004188:0.006804:0.010326:0.008104:0.010311:0.009903:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.010326:0.004188:0.012564:0.010326:0.005866:0.004188:0.004551:0.010326:0.004551:0.009827:0.003024:0.008104:0.004188:0.004747:0.009903:0.009192:0.009223:0.010357:0.004188
Reduce glucose:@0.596894:0.191744:0.673743:0.191744:0.673743:0.181857:0.596894:0.181857:0.006525:0.005886:0.006628:0.006491:0.005019:0.005886:0.002361:0.006536:0.002932:0.006491:0.005019:0.006433:0.004757:0.005886
reabsorption:@0.603259:0.198678:0.667378:0.198678:0.667378:0.188791:0.603259:0.188791:0.003958:0.005886:0.005795:0.006673:0.004757:0.006433:0.004061:0.006673:0.004004:0.002920:0.006433:0.006525
Increase:@0.827452:0.140891:0.868460:0.140891:0.868460:0.131004:0.827452:0.131004:0.003080:0.006525:0.005122:0.003958:0.005886:0.005795:0.004757:0.005886
urinary:@0.830052:0.147825:0.865859:0.147825:0.865859:0.137938:0.830052:0.137938:0.006491:0.004061:0.002920:0.006525:0.005795:0.004312:0.005704
glucose:@0.828923:0.154759:0.866977:0.154759:0.866977:0.144872:0.828923:0.144872:0.006536:0.002932:0.006491:0.005019:0.006433:0.004757:0.005886
excretion:@0.824919:0.161693:0.870981:0.161693:0.870981:0.151806:0.824919:0.151806:0.005795:0.005418:0.005122:0.003958:0.005886:0.004004:0.002920:0.006433:0.006525
Lost in:@0.886540:0.130211:0.919038:0.130211:0.919038:0.120323:0.886540:0.120323:0.005498:0.006433:0.004757:0.004004:0.002361:0.002920:0.006525
urine:@0.889848:0.137145:0.915730:0.137145:0.915730:0.127257:0.889848:0.127257:0.006491:0.004061:0.002920:0.006525:0.005886
Glucose:@0.674689:0.101980:0.713838:0.101980:0.713838:0.092093:0.674689:0.092093:0.007631:0.002932:0.006491:0.005019:0.006433:0.004757:0.005886
SGLT2:@0.721800:0.164728:0.751938:0.164728:0.751938:0.154840:0.721800:0.154840:0.005920:0.007597:0.004517:0.005989:0.006114
SGLT2:@0.723694:0.125777:0.753831:0.125777:0.753831:0.115889:0.723694:0.115889:0.005920:0.007597:0.004517:0.005989:0.006114
inhibitor:@0.717306:0.132711:0.760219:0.132711:0.760219:0.122823:0.717306:0.122823:0.002920:0.006525:0.006525:0.002920:0.006673:0.002920:0.003935:0.006433:0.004061
SGLT2 inhibitors:@0.739618:0.087861:0.819786:0.087861:0.819786:0.077974:0.739618:0.077974:0.005920:0.007597:0.004517:0.005989:0.006114:0.002361:0.002920:0.006525:0.006525:0.002920:0.006673:0.002920:0.003935:0.006433:0.004061:0.004757
suppress the action of :@0.725462:0.094796:0.836315:0.094796:0.836315:0.084908:0.725462:0.084908:0.004757:0.006491:0.006673:0.006673:0.003958:0.005886:0.004757:0.004757:0.002361:0.004004:0.006525:0.005886:0.002361:0.005795:0.005293:0.004004:0.002920:0.006433:0.006525:0.002361:0.006433:0.003639:0.002361
SGLT2:@0.764634:0.101730:0.794771:0.101730:0.794771:0.091842:0.764634:0.091842:0.005920:0.007597:0.004517:0.005989:0.006114
figure 2. mechanism of action of sGlt2 inhibitors:@0.519047:0.227719:0.872530:0.227719:0.872530:0.211221:0.519047:0.211221:0.007257:0.003629:0.009979:0.009071:0.004838:0.009676:0.004233:0.008467:0.004233:0.004233:0.013607:0.009676:0.009676:0.009071:0.009979:0.009071:0.003629:0.006652:0.014212:0.004233:0.009676:0.004233:0.004233:0.009979:0.009676:0.004536:0.003629:0.009676:0.009071:0.004233:0.009676:0.004233:0.004233:0.007862:0.012700:0.006652:0.006350:0.008467:0.004233:0.003629:0.009071:0.009071:0.003629:0.009979:0.003629:0.004536:0.009676:0.004838:0.006652
Adapted from Wright EM, :@0.519047:0.209557:0.624839:0.209557:0.624839:0.200789:0.519047:0.200789:0.006216:0.005754:0.005737:0.005728:0.002847:0.005460:0.005754:0.002327:0.002637:0.002528:0.005502:0.007879:0.002327:0.008063:0.002528:0.001680:0.005653:0.005124:0.002847:0.002327:0.004502:0.007719:0.002327:0.002327
et al. Physiol Rev. :@0.624822:0.209557:0.696436:0.209557:0.696436:0.200789:0.624822:0.200789:0.005460:0.002847:0.002327:0.005737:0.001680:0.002327:0.002327:0.004972:0.005124:0.004502:0.003259:0.001680:0.005502:0.001680:0.002327:0.005098:0.005460:0.004653:0.002327:0.002327
2011;91:733-794:@0.696427:0.209557:0.759709:0.209557:0.759709:0.200789:0.696427:0.200789:0.004653:0.004653:0.004653:0.004653:0.002327:0.004653:0.004653:0.002327:0.004653:0.004653:0.004653:0.002789:0.004653:0.004653:0.004653
figure 3. emPA-reG Primary Outcome (3-Point mACe): :@0.519047:0.930755:0.928078:0.930755:0.928078:0.914257:0.519047:0.914257:0.007257:0.003629:0.009979:0.009071:0.004838:0.009676:0.006032:0.008467:0.004233:0.006032:0.007862:0.013607:0.008467:0.011188:0.006350:0.008769:0.007862:0.012700:0.006032:0.008467:0.004838:0.003629:0.014212:0.009979:0.004838:0.008769:0.006032:0.012700:0.009071:0.004536:0.009676:0.009676:0.014212:0.009676:0.006032:0.005745:0.008467:0.006350:0.008467:0.009676:0.003629:0.009071:0.004536:0.006032:0.013607:0.011188:0.011793:0.007862:0.005745:0.004233:0.004233
CV death, nonfatal mi and nonfatal stroke:@0.519047:0.944864:0.825661:0.944864:0.825661:0.928365:0.519047:0.928365:0.011793:0.010583:0.004233:0.009979:0.009676:0.009979:0.004536:0.009071:0.004233:0.004233:0.009071:0.009676:0.009071:0.004233:0.009979:0.004536:0.009979:0.003629:0.004233:0.013607:0.004233:0.004233:0.009979:0.009071:0.009979:0.004233:0.009071:0.009676:0.009071:0.004233:0.009979:0.004536:0.009979:0.003629:0.004233:0.006652:0.004536:0.004838:0.009676:0.008769:0.009676
Zinman B, :@0.518555:0.910780:0.558268:0.910780:0.558268:0.902012:0.518555:0.902012:0.003847:0.001495:0.004939:0.007694:0.005552:0.004939:0.002142:0.004637:0.002142:0.002327
et al. N Eng J of Med:@0.558083:0.910780:0.639012:0.910780:0.639012:0.902012:0.558083:0.902012:0.005275:0.002663:0.002142:0.005552:0.001495:0.002142:0.002142:0.006031:0.002142:0.004317:0.004939:0.005468:0.002142:0.003864:0.002142:0.005317:0.002453:0.002142:0.007534:0.005275:0.005754
. 2015:@0.638827:0.910780:0.661170:0.910780:0.661170:0.902012:0.638827:0.902012:0.002142:0.002142:0.004469:0.004469:0.004469:0.004653